Remodeling domain interfaces to enhance heterodimer formation

An anti‐p185HER2/anti‐CD3 humanized bispecific diabody was previously constructed from two cross‐over single‐chain Fv in which VH and VL domains of the parent antibodies are present on different polypeptides. Here this diabody is used to evaluate domain interface engineering strategies for enhancing the formation of functional heterodimers over inactive homodimers. A disulfide‐stabilized diabody was obtained by introducing two cysteine mutations, VL L46C and VH D101C, at the anti‐p185HER2 VL/VH interface. The fraction of recovered diabody that was functional following expression in Escherichia coli was improved for the disulfide‐stabilized compared to the parent diabody (>96% versus 72%), whereas the overall yield was >60‐fold lower. Eleven “knob‐into‐hole” diabodies were designed by molecular modeling of sterically complementary mutations at the two VL/VH interfaces. Replacements at either interface are sufficient to improve the fraction of functional heterodimer, while maintaining overall recoverable yields and affinity for both antigens close to that of the parent diabody. For example, diabody variant v5 containing the mutations VL Y87A:F98M and VH V37F:L45W at the anti‐p185HER2 VL/VH interface was recovered as 92% functional heterodimer while maintaining overall recovered yield within twofold of the parent diabody. The binding affinity of v5 for p185HER2 extracellular domain and T cells is eightfold weaker and twofold stronger than for the parent diabody, respectively. Domain interface remodeling based upon either sterically complementary mutations or interchain disulfide bonds can facilitate the production of a functional diabody heterodimer. This study expands the scope of domain interface engineering by demonstrating the enhanced assembly of proteins interacting via two domain interfaces.

[1]  P. S. Kim,et al.  Peptide ‘Velcro’: Design of a heterodimeric coiled coil , 1993, Current Biology.

[2]  P. Carter,et al.  Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. , 1995, Protein Engineering.

[3]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.

[4]  P. Carter,et al.  Toward the production of bispecific antibody fragments for clinical applications. , 1995, Journal of hematotherapy.

[5]  I. Pastan,et al.  Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. , 1994, Protein engineering.

[6]  A. Fersht,et al.  Effects of engineering complementary charged residues into the hydrophobic subunit interface of tyrosyl-tRNA synthetase. Appendix: Kinetic analysis of dimeric enzymes that reversibly dissociate into inactive subunits. , 1987, Biochemistry.

[7]  T. N. Bhat,et al.  Small rearrangements in structures of Fv and Fab fragments of antibody D 1.3 on antigen binding , 1990, Nature.

[8]  I. Kuntz,et al.  Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Winter,et al.  Construction of heterodimer tyrosyl-tRNA synthetase shows tRNATyr interacts with both subunits. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. K. Schachman,et al.  Regeneration of active enzyme by formation of hybrids from inactive derivatives: implications for active sites shared between polypeptide chains of aspartate transcarbamoylase. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Ullrich,et al.  The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. , 1990, Journal of biological response modifiers.

[13]  J. Ponder,et al.  Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. , 1987, Journal of molecular biology.

[14]  R. Kelley,et al.  Thermodynamic analysis of an antibody functional epitope. , 1993, Biochemistry.

[15]  L. Presta,et al.  Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[16]  Brad Snedecor,et al.  High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment , 1992, Bio/Technology.

[17]  P. Carter,et al.  Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. , 1995, Journal of immunology.

[18]  G. Winter,et al.  A model of synthetase/transfer RNA interaction as deduced by protein engineering , 1986, Nature.

[19]  I. Pastan,et al.  A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  I. Pastan,et al.  Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. , 1994, Biochemistry.

[21]  H. K. Schachman,et al.  Shared active sites in oligomeric enzymes: model studies with defective mutants of aspartate transcarbamoylase produced by site-directed mutagenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  L. Presta,et al.  X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.

[23]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Presta,et al.  Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. , 1995, Cancer research.

[25]  B. Snedecor,et al.  High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli , 1996, Bio/Technology.